QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Forecast, Price & News

$14.91
+0.07 (+0.47%)
(As of 06/7/2023 ET)
Compare
Today's Range
$14.86
▼
$15.40
50-Day Range
$11.63
▼
$15.63
52-Week Range
$11.59
▼
$30.82
Volume
84,583 shs
Average Volume
210,192 shs
Market Capitalization
$255.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

OptimizeRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
40.8% Upside
$21.00 Price Target
Short Interest
Healthy
4.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.32mentions of OptimizeRx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.74) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Computer And Technology Sector

168th out of 596 stocks

Business Services, Not Elsewhere Classified Industry

35th out of 90 stocks

See Top Rated MarketRank™ Stocks Here

OPRX stock logo

About OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

May 30, 2023 | americanbankingnews.com
Q1 2024 EPS Estimates for OptimizeRx Co. Increased by Analyst (NASDAQ:OPRX)
May 28, 2023 | americanbankingnews.com
Analysts Set OptimizeRx Co. (NASDAQ:OPRX) Target Price at $19.20
June 7, 2023 | Vector Vest (Ad)
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
May 26, 2023 | americanbankingnews.com
SVB Leerink Equities Analysts Increase Earnings Estimates for OptimizeRx Co. (NASDAQ:OPRX)
May 25, 2023 | markets.businessinsider.com
Analysts Offer Insights on Technology Companies: OptimizeRx (OPRX) and UiPath (PATH)
May 25, 2023 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on OptimizeRx (OPRX)
May 24, 2023 | finance.yahoo.com
OptimizeRx’s CEO Provides 2023 Midyear Strategic Update
May 24, 2023 | finanznachrichten.de
OptimizeRx Corporation: OptimizeRx's CEO Provides 2023 Midyear Strategic Update
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
May 24, 2023 | benzinga.com
OptimizeRx's CEO Provides 2023 Midyear Strategic Update
May 18, 2023 | finance.yahoo.com
OptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100
May 18, 2023 | finance.yahoo.com
Revenues Tell The Story For OptimizeRx Corporation (NASDAQ:OPRX)
May 12, 2023 | msn.com
Recap: OptimizeRx Q1 Earnings
May 11, 2023 | markets.businessinsider.com
OptimizeRx (OPRX) Gets a Buy from RBC Capital
May 11, 2023 | finanznachrichten.de
OptimizeRx Corporation: OptimizeRx Reports First Quarter 2023 Financial Results
May 10, 2023 | finance.yahoo.com
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
May 10, 2023 | finance.yahoo.com
OptimizeRx Reports First Quarter 2023 Financial Results
May 4, 2023 | finance.yahoo.com
Investing in OptimizeRx (NASDAQ:OPRX) five years ago would have delivered you a 114% gain
May 3, 2023 | americanbankingnews.com
OptimizeRx (OPRX) to Release Earnings on Wednesday
May 2, 2023 | finance.yahoo.com
Surveyed Physicians Spell Out Preferences for Data-driven, Omnichannel Content That Delivers Clinical Relevance
April 30, 2023 | americanbankingnews.com
OptimizeRx Co. (NASDAQ:OPRX) Sees Large Drop in Short Interest
April 26, 2023 | finance.yahoo.com
OptimizeRx Sets First Quarter 2023 Conference Call for May 10, 2023at 4:30 p.m. ET
April 17, 2023 | finance.yahoo.com
Should You Think About Buying OptimizeRx Corporation (NASDAQ:OPRX) Now?
April 4, 2023 | finance.yahoo.com
OptimizeRx Releases 2023 Environmental, Social and Governance (ESG) Report
March 29, 2023 | finance.yahoo.com
Financial Times Ranks OptimizeRx Amongst The Americas’ Fastest Growing Companies for the Fourth Consecutive Year
March 25, 2023 | americanbankingnews.com
Analysts Issue Forecasts for OptimizeRx Co.'s Q2 2023 Earnings (NASDAQ:OPRX)
March 23, 2023 | americanbankingnews.com
William Blair Reiterates "Outperform" Rating for OptimizeRx (NASDAQ:OPRX)
See More Headlines

OPRX Price History

OPRX Company Calendar

Last Earnings
5/10/2023
Today
6/07/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Computer and Technology
Current Symbol
NASDAQ:OPRX
CUSIP
N/A
CIK
1448431
Web
www.optimizerx.com
Phone
(248) 651-6568
Fax
248-453-5529
Employees
97
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+39.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,440,000.00
Net Margins
-22.79%
Pretax Margin
-22.79%
Return on Equity
-9.27%
Return on Assets
-8.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.61
Quick Ratio
12.61

Sales & Book Value

Annual Sales
$62.45 million
Price / Sales
4.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.35 per share
Price / Book
2.04

Miscellaneous

Outstanding Shares
17,130,000
Free Float
16,374,000
Market Cap
$257.29 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Will Febbo
    Chief Executive Officer & Director
  • Edward Stelmakh
    Chief Operations & Financial Officer
  • Todd Inman
    Chief Technology Officer
  • Marion K. Odence-Ford
    Chief Compliance Officer & General Counsel
  • Angelo Campano
    Senior Vice President & Principal-Agency Channels

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OPRX Stock - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.

What is OptimizeRx's stock price forecast for 2023?

7 brokerages have issued 1 year target prices for OptimizeRx's stock. Their OPRX share price forecasts range from $16.00 to $30.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.

How have OPRX shares performed in 2023?

OptimizeRx's stock was trading at $16.80 at the beginning of the year. Since then, OPRX stock has decreased by 9.6% and is now trading at $15.19.
View the best growth stocks for 2023 here.

Are investors shorting OptimizeRx?

OptimizeRx saw a decrease in short interest in May. As of May 15th, there was short interest totaling 710,500 shares, a decrease of 19.7% from the April 30th total of 884,500 shares. Based on an average daily trading volume, of 250,800 shares, the short-interest ratio is currently 2.8 days. Approximately 4.3% of the company's shares are sold short.
View OptimizeRx's Short Interest.

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OPRX earnings forecast.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) released its earnings results on Wednesday, May, 10th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The company earned $13 million during the quarter, compared to analysts' expectations of $12.37 million. OptimizeRx had a negative net margin of 22.79% and a negative trailing twelve-month return on equity of 9.27%.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD), Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC),

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $68.69M-, compared to the consensus revenue estimate of $68.64 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.08%), First Light Asset Management LLC (5.90%), Blair William & Co. IL (4.93%), G2 Investment Partners Management LLC (3.13%), Wasatch Advisors LP (2.74%) and State Street Corp (2.47%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $15.19.

How much money does OptimizeRx make?

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $260.20 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.

This page (NASDAQ:OPRX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -